Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.
A blood test for cancer DNA tracks disease burden and treatment response in a rare, aggressive endocrine cancer lacking reliable monitoring tools.
ctDNA analysis in adrenocortical carcinoma (ACC) demonstrated prognostic value for disease burden and treatment response monitoring in this rare aggressive endocrine malignancy. ctDNA represents a promising liquid biopsy approach for a cancer type where reliable biomarkers are critically lacking.
What the study was
- Study design
- retrospective_cohort
- Category
- early_cancer_detection
- Maturity
- Validated
Why it surfaced
ctDNA application in a rare cancer type (adrenocortical carcinoma) where biomarkers are highly needed. Relevant to early cancer detection and rare diseases watchlists. MD Anderson Cancer Center-based study provides credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.